Ewa Poleszak1, Sylwia Wośko2, Anna Serefko2, Aleksandra Wlaź3, Regina Kasperek2, Jarosław Dudka4, Andrzej Wróbel5, Gabriel Nowak6, Piotr Wlaź7. 1. Department of Applied Pharmacy, Medical University of Lublin, Lublin, Poland. Electronic address: ewa.poleszak@umlub.pl. 2. Department of Applied Pharmacy, Medical University of Lublin, Lublin, Poland. 3. Department of Pathophysiology, Medical University of Lublin, Lublin, Poland. 4. Medical Biology Unit, Medical University of Lublin, Lublin, Poland. 5. Second Department of Gynecology, Medical University of Lublin, Lublin, Poland. 6. Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland; Department of Pharmacobiology, Jagiellonian University Medical College, Kraków, Poland. 7. Department of Animal Physiology, Institute of Biology and Biochemistry, Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland.
Abstract
BACKGROUND: According to reports in the literature, more than 30% of depressive patients fail to achieve remission. Therapy with the conventional antidepressant drugs may induce the serious adverse reactions. Moreover, its benefits may be seen at least 2-4 weeks after the first dose. Therefore, the alternative strategies for prevention and treatment of depression are sought. The main aim of our study was to assess the effects of ifenprodil given at a non-active dose (10mg/kg) on the activity of antidepressant agents from diverse pharmacological groups. METHODS: The antidepressant-like effect was assessed by the forced swim test in mice. RESULTS: Ifenprodil potentiated the antidepressant-like effect of imipramine (15mg/kg) and fluoxetine (5mg/kg) while did not reduce the immobility time of animals which simultaneously received reboxetine (2.5mg/kg) or tianeptine (15mg/kg). CONCLUSION: The concomitant administration of certain commonly prescribed antidepressant drugs that affect the serotonergic neurotransmission (i.e., typical tricyclic antidepressants and selective serotonin reuptake inhibitors) with a negative modulator selectively binding to the GluN1/N2B subunits of the NMDA receptor complex (i.e., ifenprodil) may induce a more pronounced antidepressant-like effect than monotherapy. However, these findings still need to be confirmed in further experiments.
BACKGROUND: According to reports in the literature, more than 30% of depressivepatients fail to achieve remission. Therapy with the conventional antidepressant drugs may induce the serious adverse reactions. Moreover, its benefits may be seen at least 2-4 weeks after the first dose. Therefore, the alternative strategies for prevention and treatment of depression are sought. The main aim of our study was to assess the effects of ifenprodil given at a non-active dose (10mg/kg) on the activity of antidepressant agents from diverse pharmacological groups. METHODS: The antidepressant-like effect was assessed by the forced swim test in mice. RESULTS:Ifenprodil potentiated the antidepressant-like effect of imipramine (15mg/kg) and fluoxetine (5mg/kg) while did not reduce the immobility time of animals which simultaneously received reboxetine (2.5mg/kg) or tianeptine (15mg/kg). CONCLUSION: The concomitant administration of certain commonly prescribed antidepressant drugs that affect the serotonergic neurotransmission (i.e., typical tricyclic antidepressants and selective serotonin reuptake inhibitors) with a negative modulator selectively binding to the GluN1/N2B subunits of the NMDA receptor complex (i.e., ifenprodil) may induce a more pronounced antidepressant-like effect than monotherapy. However, these findings still need to be confirmed in further experiments.
Authors: Jonna M Leyrer-Jackson; Jose A Piña; Joseph McCallum; M Foster Olive; Cassandra D Gipson Journal: Brain Struct Funct Date: 2020-06-26 Impact factor: 3.270
Authors: Ewa Poleszak; Weronika Stasiuk; Aleksandra Szopa; Elżbieta Wyska; Anna Serefko; Anna Oniszczuk; Sylwia Wośko; Katarzyna Świąder; Piotr Wlaź Journal: Metab Brain Dis Date: 2016-02-29 Impact factor: 3.584